Multimorbidity in patients with atrial fibrillation

被引:1
|
作者
Lobeek, Michelle [1 ]
Middeldorp, Melissa E. [1 ]
Van Gelder, Isabelle C. [1 ]
Rienstra, Michiel [1 ]
机构
[1] Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
来源
OPEN HEART | 2024年 / 11卷 / 01期
关键词
Atrial Fibrillation; RISK FACTORS; Pharmacology; RISK-FACTOR; LIFE-STYLE; REDUCTION; DISEASES; BURDEN; IMPACT; CARE;
D O I
10.1136/openhrt-2024-002641
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is an escalating trend in both the incidence and prevalence of atrial fibrillation (AF). AF is linked to numerous other comorbidities, contributing to the emergence of multimorbidity. The sustained rise in multimorbidity and AF prevalences exerts a significant strain on healthcare systems globally. The understanding of the relation between multimorbidity and AF is essential to determine effective healthcare strategies, improve patient outcomes to adequately address the burden of AF. It not only begins with the accurate identification of comorbidities in the setting of AF. There is also the need to understand the pathophysiology of the different comorbidities and their common interactions, and how multimorbidity influences AF perpetuation. To manage the challenges that rise from the increasing incidence and prevalence of both multimorbidity and AF, such as adverse events and hospitalisations, the treatment of comorbidities in AF has already gained importance and will need to be a primary focus in the forthcoming years. There are numerous challenges to overcome in the treatment of multimorbidity in AF, whereby the identification of comorbidities is essential. Integrated care strategies focused on a comprehensive multimorbidity management with an individual-centred approach need to be determined to improve healthcare strategies and reduce the AF-related risk of frailty, cardiovascular diseases and improve patient outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Cardiometabolic multimorbidity and lifetime risk of atrial fibrillation among men and women
    Lu, Z.
    Ntlapto, N.
    Tilly, M.
    Ikram, M. A.
    De Groot, N. M. S.
    Kavousi, M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2241 - 2241
  • [32] Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?
    Martinez-Montesinos, Lorena
    Rivera-Caravaca, Jose Miguel
    Agewall, Stefan
    Soler, Eva
    Lip, Gregory Y. H.
    Marin, Francisco
    Roldan, Vanessa
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 158
  • [33] Multimorbidity in atrial fibrillation for clinical implications using the Charlson Comorbidity Index
    Jung, Moonki
    Yang, Pil -Sung
    Kim, Daehoon
    Sung, Jung-Hoon
    Jang, Eunsun
    Yu, Hee Tae
    Kim, Tae-Hoon
    Uhm, Jae-Sun
    Pak, Hui -Nam
    Lee, Moon-Hyoung
    Joung, Boyoung
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 398
  • [34] Asymptomatic atrial fibrillation in patients with atrial fibrillation and implanted pacemaker
    Witkowski, Michal
    Bissinger, Andrzej
    Grycewicz, Tomasz
    Lubinski, Andrzej
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 : 583 - 588
  • [35] Atrial fibrillation inducibility in patients with no prior atrial fibrillation.
    Boonyapisit, Warangkna
    Mukerji, Siddharth
    Chen-Scarabelli, Carol
    McLemore, Rita
    Pelosi, Frank
    Oral, Hakan
    Bogun, Frank
    Chugh, Aman
    Good, Eric
    Thakur, Ranjan
    Morady, Fred
    Jongnarangsin, Krit
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 14A - 14A
  • [36] Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
    Steven Deitelzweig
    Allison Keshishian
    Amiee Kang
    Amol D. Dhamane
    Xuemei Luo
    Christian Klem
    Lisa Rosenblatt
    Jack Mardekian
    Jenny Jiang
    Huseyin Yuce
    Gregory Y. H. Lip
    Advances in Therapy, 2021, 38 : 3166 - 3184
  • [37] Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
    Deitelzweig, Steven
    Keshishian, Allison
    Kang, Amiee
    Dhamane, Amol D.
    Luo, Xuemei
    Klem, Christian
    Rosenblatt, Lisa
    Mardekian, Jack
    Jiang, Jenny
    Yuce, Huseyin
    Lip, Gregory Y. H.
    ADVANCES IN THERAPY, 2021, 38 (06) : 3166 - 3184
  • [38] Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study
    Chamberlain, Alanna M.
    Alonso, Alvaro
    Gersh, Bernard J.
    Manemann, Sheila M.
    Killian, Jill M.
    Weston, Susan A.
    Byrne, Margaret
    Roger, Veronique L.
    AMERICAN HEART JOURNAL, 2017, 185 : 74 - 84
  • [39] Multimorbidity management in atrial fibrillation: The Polish perspective in the EHRA-PATHS study
    Lee, Geraldine A.
    Farkowski, Michal M.
    Baker, Edward
    Sterlinski, Maciej
    van Gelder, Isabelle C.
    Dabrowski, Rafal
    Desteghe, Lien
    Szumowski, Lukasz
    Merino, Jose L.
    Collins, Ronan
    Rienstra, Michiel
    Heidbuchel, Hein
    KARDIOLOGIA POLSKA, 2023, 81 (06) : 580 - 586
  • [40] Individualized therapy in patients with atrial fibrillation: new look at atrial fibrillation
    Shenasa, Mohammad
    Soleimanieh, Mona
    Shenasa, Fatemah
    EUROPACE, 2012, 14 : V121 - V124